Some limitations of our pilot study should be pointed out: small sample size, no dividing AD patients into subtypes (intrinsic vs. extrinsic), no relations between other biochemical markers (i.e., IgE level, CCL17 and CCL18) and no other scores for AD severity (i.e., EASI) have been investigated. The gene discussed is CCL17; the disease is Alzheimer disease.